Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France.
Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K; TREAT-NMD Neuromuscular Network. Mercuri E, et al. Neuromuscul Disord. 2008 Nov;18(11):894-903. doi: 10.1016/j.nmd.2008.07.003. Epub 2008 Sep 24. Neuromuscul Disord. 2008. PMID: 18818076 No abstract available.
Best practice in Duchenne muscular dystrophy.
Buccella F, Furlong P, Hofmeister S, Vroom E. Buccella F, et al. Among authors: vroom e. Neuromuscul Disord. 2010 Mar;20(3):216-7; author reply 218-9. doi: 10.1016/j.nmd.2010.02.006. Epub 2010 Mar 4. Neuromuscul Disord. 2010. PMID: 20206518 No abstract available.
Transition in Duchenne muscular dystrophy: An expert meeting report and description of transition needs in an emergent patient population: (Parent Project Muscular Dystrophy Transition Expert Meeting 17-18 June 2011, Amsterdam, The Netherlands).
Schrans DG, Abbott D, Peay HL, Pangalila RF, Vroom E, Goemans N, Vles JS, Aldenkamp AP, Hendriksen JG; Expert Meeting Participants on Transition and Adulthood in Duchenne Muscular Dystrophy. Schrans DG, et al. Among authors: vroom e. Neuromuscul Disord. 2013 Mar;23(3):283-6. doi: 10.1016/j.nmd.2012.08.009. Epub 2012 Sep 16. Neuromuscul Disord. 2013. PMID: 22989602 No abstract available.
Biomarkers and surrogate endpoints in Duchenne: meeting report.
Aartsma-Rus A, Ferlini A, Vroom E. Aartsma-Rus A, et al. Among authors: vroom e. Neuromuscul Disord. 2014 Aug;24(8):743-5. doi: 10.1016/j.nmd.2014.03.006. Epub 2014 May 28. Neuromuscul Disord. 2014. PMID: 24951452 No abstract available.
Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy.
Lynn S, Aartsma-Rus A, Bushby K, Furlong P, Goemans N, De Luca A, Mayhew A, McDonald C, Mercuri E, Muntoni F, Pohlschmidt M, Verschuuren J, Voit T, Vroom E, Wells DJ, Straub V. Lynn S, et al. Among authors: vroom e. Neuromuscul Disord. 2015 Jan;25(1):96-105. doi: 10.1016/j.nmd.2014.09.003. Epub 2014 Sep 11. Neuromuscul Disord. 2015. PMID: 25307856 No abstract available.
83 results